| Document Date: 2013-12-31 12:39:20
Open Document File Size: 784,81 KBShare Result on Facebook
Company Michel Sadelain / LTR SA / PhD Agenda / / Country United States / / Event Business Partnership / FDA Phase / / Facility Reilly’s Laboratory / / IndustryTerm treatment of residual or relapsed acute lymphoblastic leukemia / / MedicalCondition acute lymphoblastic leukemia / Childhood ALL / B cell lymphomas / JE / Cancer / Asymptomatic/Infectious Mononucleosis / leukemias / CD19+ leukemia / / MedicalTreatment Bone Marrow Transplant / / Organization Department of Pediatrics / Richard J. O’Reilly’s Laboratory / / Person Nancy A. Kernan / Kevin Curran / Pediatric Patients / Renier Brentjens / Barr Virus Cytotoxic / Isabelle Riviere / / Product CD19 / / Technology transplantation / stem cells / /
SocialTag |
OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In